This article examines the critical success factors for PEGylated therapies and the decision-making process for when a custom PEG may be warranted rather than an off-the-shelf solution. The essential role of a contract development and manufacturing organization (CDMO) with deep expertise in activated PEG chemistry is highlighted.
Authors: Raymond Behrendt, Silvia Kaden-Vagt, Lotfi Bouchekioua, Merck KGaA, Darmstadt, Germany
German pharma association publishes clinical trial ranking
Latest NewsThe German pharmaceutical association vfa has updated its ranking of the best locations for industry-sponsored clinical trials. In Europe, Spain retained its top position in 2024, followed by Australia, Germany, the UK, and France.
RadioMedix expands thorium-228 supply for 212Pb
Latest NewsRadiopharmaceuticals specialist RadioMedix Inc has secured five-year Thorium-228 supply from Van Overeem, strengthening 212Pb production and Targeted Alpha Therapy pipeline development.
Berlin: Why Start-ups Choose Bayer Co.Lab
BackgroundOne year after the inauguration of Bayer Co.Lab — the open workspace for start-ups in Berlin — it is time to take stock. European Biotechnology News Magazine
spoke with tenants and with Dr Ruth Shah, Head of Bayer Co.Lab Berlin, about the concept, the offering, and the feedback Bayer has received so far.
Zealand pays Chinese OTR US$30m upfront to expand obesity pipeline
Latest NewsDanish Zealand Pharma A/S partners with Chinese start-up OTR Therapeutics Co. Ltd to expand oral obesity pipeline in US$30m upfront deal.
Lilly‘s retatrutide delivers record weight loss
Latest NewsLilly’s triple weight loss combination therapy retatrutide has shown 28.7% weight loss in Phase 3, but higher discontinuations vs. tirzepatide and semaglutide.
Pfizer presents data for Tukysa in HER2-positive breast cancer
Latest NewsPfizer’s Tukysa improves progression-free survival in first-line HER2-positive breast cancer, especially in HR-negative patients, with manageable safety. Data were shown at the 2025 San Antonio Breast Cancer Symposium.
Roche presents details on breast cancer pill giredestrant
Latest NewsRoche has unveiled detailed data for its oral selective estrogen receptor degrader (SERD), giredestrant, at the 2025 San Antonio Breast Cancer Symposium.
Disco Pharmaceuticals GmbH expands seed financing
Latest NewsCologne-based Disco Pharmaceuticals GmbH has closed its seed financing at €36m. The company will use the proceeds to advance its surfaceome-mapping platform, developing bispecific ADCs and T-Cell Engagers for hard-to-treat cancers.
Tetraneuron secures funding for Alzheimer’s gene therapy trial
Latest NewsSpanish Tetraneuron secures financing to advance its E2F4DN-based Alzheimer’s gene therapy, restoring neuronal homeostasis and halting disease progression in Europe.
Selecting a CDMO for Custom Activated PEGs
Sponsored PublicationsThis article examines the critical success factors for PEGylated therapies and the decision-making process for when a custom PEG may be warranted rather than an off-the-shelf solution. The essential role of a contract development and manufacturing organization (CDMO) with deep expertise in activated PEG chemistry is highlighted.
Authors: Raymond Behrendt, Silvia Kaden-Vagt, Lotfi Bouchekioua, Merck KGaA, Darmstadt, Germany